Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.
Vertex Pharmaceuticals Incorporated (VRTX), headquartered ... author and do not necessarily reflect those of Nasdaq, Inc. With headquarters in the heart of Chicago's financial district, Barchart ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Vertex Pharmaceuticals Inc. closed $106.51 short of its 52-week high ($519.88), which the company reached on November 8th.
International Assets Investment Management LLC lowered its position in shares of Vertex Pharmaceuticals Incorporated ...